Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody-Reference-Cited by-同舟云学术

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

Published:2017-02-21 Issue:1 Volume:5 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Donahue Renee N.,Lepone Lauren M.,Grenga Italia,Jochems Caroline,Fantini Massimo,Madan Ravi A.,Heery Christopher R.,Gulley James L.,Schlom Jeffrey^ORCID

Funder

EMD Serono

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-017-0220-y.pdf

Reference35 articles.

1. Callahan MK, et al. Targeting T cell co-receptors for cancer therapy. Immunity. 2016;44:1069–78.

2. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235–47.

3. Boyerinas B, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148–57.

4. Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016;7:33498–511.

5. Khanna S, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11:1993–200.

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;Nature Communications;2024-03-27

2. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-01

3. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;2023-12-04

4. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients;Cancer Immunology, Immunotherapy;2023-10-10

5. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma;Journal for ImmunoTherapy of Cancer;2023-05